Variable | n | % rate |
---|---|---|
HCV, hepatitis C virus; HBV, hepatitis B virus; PEI, percutaneous ethanol injection; TACE, transarterial chemoembolisation; RFA, radiofrequency ablation. | ||
Sex | ||
Male/female | 204/64 | 76.1–33.9% |
Liver disease | ||
Chronic hepatitis | 9 | 4.1% |
Cirrhosis | 259 | 95.9% |
Child-Pugh Class A | 209 | 80.5% |
Child-Pugh Class B | 50 | 19.4% |
Aetiology | ||
HCV | 187 | 69.7% |
HBV | 47 | 17.5% |
HBV+HCV | 16 | 6.0% |
Alcohol | 14 | 5.2% |
Unknown | 6 | 2.2% |
Ascites | ||
Absent/present | 236/32 | 88.1–11.9% |
Portal vein thrombosis | ||
Absent/present | 257/11 | 95.9–4.1% |
No of HCC nodules | ||
Single/multiple | 155/113 | 57.8–42.2% |
Diameter of (largest) HCC nodule | ||
<3 cm/>3 cm | 125/143 | 45.9–54.1% |
Treatment | ||
PEI | 132 | 49.2% |
TACE | 103 | 38.4% |
RFA | 14 | 5.2% |
Supportive | 19 | 7.2% |